Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects

• DWP14012 (Drug): Potassium-competitive acid blocker
• DWC202202 (Drug): Clopidogrel Bisulfate
• DWC202203 (Drug): Proton pump inhibitor

Primary outcomes

• Emax [up to 50 days]
• AUEC0-24 [up to 50 days]

Secondary outcomes

• DWC202202 Cmax,ss [up to 50 days]
• DWC202202 active metabolite Cmax,ss [up to 50 days]
• DWC202202 AUCtau,ss [up to 50 days]
• DWC202202 active metabolite AUCtau,ss [up to 50 days]
• DWC202202 AUCinf,ss [up to 50 days]
• DWC202202 active metabolite AUCinf,ss [up to 50 days]
• DWC202202 Tmax,ss [up to 50 days]
• DWC202202 active metabolite Tmax,ss [up to 50 days]
• DWC202202 t1/2,ss [up to 50 days]
• DWC202202 active metabolite t1/2,ss [up to 50 days]
• DWC202202 Cmin,ss [up to 50 days]
• DWC202202 active metabolite Cmin,ss [up to 50 days]
• DWC202202 Cavg,ss [up to 50 days]
• DWC202202 active metabolite Cavg,ss [up to 50 days]
• DWC202202 CLss/F [up to 50 days]
• DWC202202 Vd,ss/F [up to 50 days]
• DWC202202 PTF (peak to trough fluctuation) [up to 50 days]
• DWC202202 active metabolite PTF (peak to trough fluctuation) [up to 50 days]
• DWC202202 R [up to 50 days]
• DWC202202 active metabolite MR [up to 50 days]

Sex: All, ages: 19 Years to 50 Years, accepts healthy volunteers

Inclusion Criteria:

* Healthy adults aged ≥ 19 and ≤ 50 years at screening
* Subjects with a body weight ≥ 50.0 kg to ≤ 90.0 kg with a body mass index (BMI) of ≥ 18.0 kg/m2 to ≤ 27.0 kg/m2 at screening

  ※ BMI (kg/m2) = body weight (kg)/\[height (m)\]2
* Subjects who voluntarily decided to participate in the study and provided written consent to follow precautions after receiving a sufficient explanation on this study and fully understanding the information
* Subjects who are eligible to participate in the study at the discretion of the investigator by physical examination, laboratory tests, and investigator questioning, etc.

Exclusion Criteria:

* Subjects with a history related to blood clotting disorder or bleeding
* Subjects with hypersensitivity or history of clinically significant hypersensitivity to drugs including potassium competitive acid blocker \[P-CAB\] class, aspirin, antibiotics, etc.
* Subjects with a history of drug abuse or a positive result of using abusive drugs in the urine drug screen
* Subjects who participated in other clinical trials (including bioequivalence studies) within 6 months prior to the first scheduled dose of the IP
* Subjects who donated whole blood within 2 months, donated blood components within 1 month, or received blood transfusion within 1 month prior to the first scheduled dose
* Subjects who are unable to refrain from grapefruit-containing products from 3 days prior to the first scheduled dose until last discharge from hospital
* Subjects with hereditary disorders including galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption, etc.
* Subjects or their spouses or partners who are unable to use medically acceptable appropriate double-method of contraception or medically acceptable contraception throughout the study period and for at least 4 weeks after the last IP administration
* Subjects who are smoking